Simple search of free and LexisNexis legal content for Australia
– legislation, cases, practical guidance, forms & precedents, journals and newsletters.

                                                                                                                                                                               History

Reckitt Benckiser (Australia) Pty Ltd V Glaxosmithkline Australia Pty Ltd

Federal Court of Australia

Judgment Date:
2018-08-24

Abstract:
A comparative advertising campaign in which Reckitt Benckiser (Australia) Pty Ltd compared its product Nurofen and its active ingredient ibuprofen with a competing product, Panadol and its active ingredient paracetamol, was found to be misleading or deceptive, or likely to mislead or deceive. The Federal Court of Australia Full Court affirmed the Federal Court of Australia's findings that the balance of scientific evidence demonstrated no clear-cut superiority of ibuprofen over paracetamol in terms of faster and more effective relief from pain caused by common headaches.

Trade and commerce | Trade practices | Advertising | Misleading and deceptive conduct

Published:
14/09/2018
Log In


X

Suggest a site


Suggestion Sent!

Thank you for your feedback
Close
X

Request a Callback


Request Sent!

We will get back to you shortly.
Close

History Close

Share


To Email:
Message:

Send

Message Sent!

to

Close